Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

About this market

COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. exposure to second-hand or passive smoking. smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status. and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders. which contribute to the rising prevalence of COPD. Technavio’s analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Strong pipeline and new drug approvals

The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.

Low diagnosis rates for COPD

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view our report.

Competitive Landscape

The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global respiratory disorder drugs market
      • Table Segments of global respiratory disorder drugs market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Pipeline analysis
    • Table Pipeline molecules for COPD
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Combination therapy - Market size and forecast 2018-2023
      • Table Combination therapy - Market size and forecast 2018-2023 ($ millions)
      • Table Combination therapy - Year-over-year growth 2019-2023 (%)
    • Monotherapy - Market size and forecast 2018-2023
      • Table Monotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Monotherapy - Year-over-year growth 2019-2023 (%)
      • Table Sales of monotherapy drugs 2015-2017 ($ millions)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Market segmentation by type
    • Chronic bronchitis
    • Emphysema
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
      • Table New drug approvals for COPD
      • Table US FDA-approved fixed-dose combination LABAs and LAMAs
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Table Examples of advanced nebulizers
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AstraZeneca
      • Table AstraZeneca - Vendor overview
      • Table AstraZeneca - Business segments
      • Table AstraZeneca - Organizational developments
      • Table AstraZeneca - Geographic focus
      • Table AstraZeneca - Key offerings
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim - Vendor overview
      • Table Boehringer Ingelheim - Business segments
      • Table Boehringer Ingelheim - Organizational developments
      • Table Boehringer Ingelheim - Geographic focus
      • Table Boehringer Ingelheim - Segment focus
      • Table Boehringer Ingelheim - Key offerings
    • GlaxoSmithKline
      • Table GlaxoSmithKline - Vendor overview
      • Table GlaxoSmithKline - Business segments
      • Table GlaxoSmithKline - Organizational developments
      • Table GlaxoSmithKline - Geographic focus
      • Table GlaxoSmithKline - Segment focus
      • Table GlaxoSmithKline - Key offerings
    • Novartis
      • Table Novartis - Vendor overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
    • Teva Pharmaceutical
      • Table Teva Pharmaceutical - Vendor overview
      • Table Teva Pharmaceutical - Business segments
      • Table Teva Pharmaceutical - Organizational developments
      • Table Teva Pharmaceutical - Geographic focus
      • Table Teva Pharmaceutical - Segment focus
      • Table Teva Pharmaceutical - Key offerings
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook